Integrated Filing (Financial) for the quarter and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals reported a weak FY25 with a net loss of Rs. 70.87 lakhs, swinging from a profit of Rs. 19.74 lakhs in FY24. Full-year revenue from operations declined to Rs. 673.96 lakhs from Rs. 695.73 lakhs (about 3% lower YoY). Operating cash flow turned sharply negative at Rs. (62.22) lakhs versus a positive Rs. 182.24 lakhs last year, driven mainly by a large jump in trade receivables. The company's current borrowings surged 49% to Rs. 871.34 lakhs while total equity shrank to Rs. 482.85 lakhs from Rs. 554.71 lakhs due to accumulated losses. Loss per share for the year stood at Rs. (1.54) versus EPS of Rs. 0.43 in FY24. The auditor (Pulindra Patel & Co.) issued an unqualified (clean) opinion on the results.
Shareholders should note the swing to a loss, negative operating cash flow, and rising debt levels — the company is funding operations through additional short-term borrowings rather than internal cash generation. The clean audit opinion is a positive, but the overall financial trajectory is concerning for near-term stock sentiment.